Completed
Topical A-007 for Advanced Malignancies, Kaposi's Sarcoma and Lymphoproliferative Disorders
What is being tested
A-007
Drug
Who is being recruted
Blood-Borne Infections+29
+ Urogenital Diseases
+ Genital Diseases
Over 21 Years
+20 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 1
Interventional
Summary
Principal SponsorDEKK-TEC, Inc.
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
This study focuses on the use of a drug called 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone, or A-007, in treating advanced cancers, including Kaposi's sarcoma and lymphoproliferative disorders. These are conditions where abnormal cells grow uncontrollably, causing harm to the body. The study aims to evaluate how well A-007 works when applied directly to the skin, offering a potential new approach to treating these serious diseases.
Principal SponsorDEKK-TEC, Inc.
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
25 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 21 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesDNA Virus InfectionsHemic and Lymphatic DiseasesHerpesviridae InfectionsImmunologic Deficiency SyndromesImmune System DiseasesImmunoproliferative DisordersInfectionsLymphatic DiseasesNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Vascular TissueRetroviridae InfectionsRNA Virus InfectionsSarcomaSexually Transmitted DiseasesSkin DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsSkin and Connective Tissue DiseasesNeoplasms, Connective and Soft TissueAcquired Immunodeficiency SyndromeLymphoproliferative DisordersSarcoma, KaposiSkin NeoplasmsHIV Infections
Criteria
7 inclusion criteria required to participate
Failed both primary and secondary chemotherapy and/or immunotherapy protocols
Histologically proven metastatic cancer including Kaposi's sarcoma and lymphoproliferative disorders to the skin or cutaneous sites. NOTE: Primary basal or squamous cell cancer of the skin is allowed
Life expectancy of at least 20 weeks
Maintenance antihormones, hormones, and glucocorticoids are allowed
Show More Criteria
13 exclusion criteria prevent from participating
Active congestive heart failure, any persistent arrhythmia or transient serious arrhythmia (ventricular tachycardia, sinoatrial arrest, etc.), or progressive cardiomyopathy
Active infections other than medically stable HIV infection
Any other medical conditions that would prevent completion of study or produce significant risk to patient
Coagulopathies
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center